UK Parkinson's Disease Consortium - UKPDC
- Principal Investigators
- Research Groups
- Cell Physiology
- Clinical Neuroscience
- Clinical Studies
- Drosophila Genetics
- Molecular Biology and Biochemistry
- Molecular Neuropathology
- Neurological Biochemistry
- Neurological Signalling
- Protein Phosphorylation
- Contact us
A study published in Brain, led by researchers
at UCL Institute of Neurology, has shown that genetic mutations which
cause a decrease in dopamine
production in the brain and lead to a form of childhood-onset Dystonia,
also play a role in the development of Parkinson’s disease.
The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
In this paper Claudia Manzoni studies how fibroblast
cells from people with Parkinson’s disease caused by mutations in LRRK2
react to starvation. Although the changes are quite subtle, there are
differences between the way that fibroblasts that contain mutant LRRK2
respond to being starved – suggesting that there may be changes in the
way that these cells regulate a key process called autophagy (a term
which comes from the greek meaning to eat yourself, and is one of the
ways that cells get rid of waste and recycle proteins and organellles).
Research led by consortium researchers Dr Helene Plun-Favreau (UCL Institute of Neurology) and Dr Alex Whitworth (University of Sheffield), and collaborator Dr Heike Laman (University of Cambridge), has discovered how genetic mutations linked to Parkinson’s disease might play a key role in the death of brain cells, potentially paving the way for the development of more effective drug treatments. In the new study, published in Nature Neuroscience, the team of cross-institutional researchers showed how defects in the Parkinson’s gene Fbxo7 cause problems with mitophagy. More...
Mutations in LRRK2 are the most common genetic cause of Parkinson’s disease. Here, Claudia Manzoni talks about her research (funded by the Rosetrees Trust and the Michael J. Fox Foundation) into what LRRK2 might be doing within the cell: Parkinson’s disease is a brain illness that afflicts 1 in 500 people in the UK. High profile patients, such as the actor Michael J Fox, the boxer Muhammad Ali and the late Pope John Paul II, have raised public awareness of Parkinson’s and its devastating impact. More...
Rohan de Silva
Born in Sri Lanka, Rohan obtained his degree in Biochemistry in 1987 (Universität Bern, Switzerland) and a D.Phil. in Molecular Biology, 1991 (Oxford University). From 1991-1995 he worked at Duke University Medical Center, North Carolina (genetics of Alzheimer’s Disease), where he was involved with the first identification of mutations in the presenilin-1 gene and, in collaboration with the late Dr Tsunao Saitoh (UCSD) first identified promoter variants of the alpha-synuclein gene (SNCA) that are now associated with Parkinson’s disease risk. In 1995-1996, he briefly worked at the Marie Curie Research Institute in Oxted, Surrey (genetics of bladder cancer) and 1996-1999 at Imperial College School of Medicine (investigation of role of cytokines in amyloid precursor protein gene expression and splicing). Since 1999 he has been at the RLWI where he has been working on the genetics, biochemistry and cell biology of Parkinson’s disease, progressive supranuclear palsy and related disorders. His primary interests are the investigation of the tau (MAPT) and SNCA genes and their roles in neurodegeneration.
|Link to publications|
Page last modified on 20 mar 13 16:45